Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen
Estrellita Uijl, Katrina M. Mirabito Colafella, Yuan Sun, et al.
Hypertension (2019) Vol. 73, Iss. 6, pp. 1249-1257
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
Lauren B. Arendse, A.H. Jan Danser, Marko Poglitsch, et al.
Pharmacological Reviews (2019) Vol. 71, Iss. 4, pp. 539-570
Open Access | Times Cited: 315
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
Akshay S. Desai, David J. Webb, Jörg Täubel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 3, pp. 228-238
Open Access | Times Cited: 156
The renin-angiotensin-aldosterone system and its therapeutic targets
Katrina M. Mirabito Colafella, Dominique M. Bovée, A.H. Jan Danser
Experimental Eye Research (2019) Vol. 186, pp. 107680-107680
Closed Access | Times Cited: 154
RNA-targeting and gene editing therapies for transthyretin amyloidosis
Alberto Aimo, Vincenzo Castiglione, Claudio Rapezzi, et al.
Nature Reviews Cardiology (2022) Vol. 19, Iss. 10, pp. 655-667
Closed Access | Times Cited: 118
RNA Interference With Zilebesiran for Mild to Moderate Hypertension
George L. Bakris, Manish Saxena, Anil Gupta, et al.
JAMA (2024) Vol. 331, Iss. 9, pp. 740-740
Open Access | Times Cited: 61
Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
Soraya Puglisi, Alessandro Rossini, Roberta Poli, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 89
Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies
Trupti Ghatage, Srashti Goyal, Arti Dhar, et al.
Hypertension Research (2021) Vol. 44, Iss. 7, pp. 740-755
Open Access | Times Cited: 65
Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx
Erin Morgan, Yvonne Tami, Kuolung Hu, et al.
JACC Basic to Translational Science (2021) Vol. 6, Iss. 6, pp. 485-496
Open Access | Times Cited: 63
Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease
Edwyn O. Cruz‐López, Dien Ye, Congqing Wu, et al.
Hypertension (2022) Vol. 79, Iss. 10, pp. 2115-2126
Open Access | Times Cited: 50
The role of adherence in patients with chronic diseases
Michel Burnier
European Journal of Internal Medicine (2023) Vol. 119, pp. 1-5
Open Access | Times Cited: 27
Small Interfering RNA Therapy for the Management and Prevention of Hypertension
Liwei Ren, A.H. Jan Danser
Current Hypertension Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 1
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Matthew Sayer, David J. Webb, Neeraj Dhaun
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 1
The evolving complexity of the collecting duct renin–angiotensin system in hypertension
Minolfa C. Prieto, Alexis A. González, Bruna Visniauskas, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 7, pp. 481-492
Open Access | Times Cited: 43
The renin–angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts
Carlos M. Ferrario, Leanne Groban, Hao Wang, et al.
Kidney International Supplements (2022) Vol. 12, Iss. 1, pp. 36-47
Open Access | Times Cited: 37
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Hui Lin, Frank Geurts, Luise Hassler, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 462-505
Open Access | Times Cited: 37
Conventional Vasopressor and Vasopressor‐Sparing Strategies to Counteract the Blood Pressure–Lowering Effect of Small Interfering RNA Targeting Angiotensinogen
Estrellita Uijl, Dien Ye, Liwei Ren, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 15
Open Access | Times Cited: 33
Arterielle Hypertonie – Eine Übersicht für den ärztlichen Alltag
Felicitas E. Hengel, Christian Sommer, Ulrich Wenzel
DMW - Deutsche Medizinische Wochenschrift (2022) Vol. 147, Iss. 07, pp. 414-428
Closed Access | Times Cited: 29
Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR
Dien Ye, Edwyn O. Cruz‐López, Richard van Veghel, et al.
Hypertension (2024) Vol. 81, Iss. 7, pp. 1491-1499
Open Access | Times Cited: 8
Human kidney organoids produce functional renin
Anusha S. Shankar, Zhaoyu Du, Héctor Tejeda Mora, et al.
Kidney International (2020) Vol. 99, Iss. 1, pp. 134-147
Open Access | Times Cited: 50
Hypertension: Current trends and future perspectives
Paul G. Hunter, Fiona A. Chapman, Neeraj Dhaun
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 10, pp. 3721-3736
Open Access | Times Cited: 36
The mechanisms of renin–angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures
Haifeng Zhang, Xiang Gao, Xuan Wang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111868-111868
Open Access | Times Cited: 36
First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension
Horng H. Chen, Siu‐Hin Wan, Seethalakshmi Iyer, et al.
Hypertension (2021) Vol. 78, Iss. 6, pp. 1859-1867
Open Access | Times Cited: 36
Angiotensinogen
Tanvir Kahlon, Samantha M. Carlisle, Diana Otero Mostacero, et al.
JACC Heart Failure (2022) Vol. 10, Iss. 10, pp. 699-713
Open Access | Times Cited: 23
Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics
Melisande Addison, Priyanga Ranasinghe, David J. Webb
Hypertension (2023) Vol. 80, Iss. 11, pp. 2243-2254
Closed Access | Times Cited: 14
Zilebesiran: A Promising Antihypertensive Therapy Inhibiting Angiotensinogen Synthesis
Rida S. Khan, William H. Frishman
Cardiology in Review (2024)
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top